Initial Study Demonstrates that VolitionRx NuQ® Blood Test Has 84% Accuracy in Detecting Early Stage Treatable Pancreatic Cancers
VolitionRx to Initiate Study with University Hospital Bonn to Confirm NuQ® Test Accuracy in Lung Cancer
VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014
VolitionRx Enters Agreement with University of Oxford to Initiate Endometriosis Study
VolitionRx to Present at the SeeThruEquity Conference
VolitionRx Initiates Sponsorship of Two-time Cancer Survivor to Drive Awareness for the Importance of Early Cancer Detection
VolitionRx Presents Further Colorectal Cancer Data at 9th International Conference of Anticancer Research
VolitionRx Announces Prostate Cancer Collaboration with the University of Texas MD Anderson Cancer Center
VolitionRx NuQ(R) Blood Test Detects 84% of Colorectal Cancers; Including Both Early- and Later-stage Cancers
VolitionRx to Present at the Aegis Capital Corp. 2014 Healthcare & Technology Conference
